Women with the common reproductive and metabolic condition polycystic ovary syndrome (PCOS) face a greater risk of developing bulimia, binge eating disorder, and disordered eating, according to new research published in The Journal of Clinical Endocrinology & Metabolism. PCOS affects roughly one in eight women. Women who have the condition face an increased risk of developing...
Revised Version of TROA Passes House Ways & Means Committee On June 27, 2024, the House Ways and Means Committee passed a revised version of the Treat and Reduce Obesity Act (TROA), legislation that would allow Medicare coverage of anti-obesity medications (AOMs), which currently is prohibited under law. The version that passed would only allow...
New International Guideline-Writing Partnership Debuts at ENDO 2024
While at ENDO 2024 in Boston, the Endocrine Society and European Society of Endocrinology together released the first in a series of guidelines co-authored by the societies. The “European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency” will better prepare endocrinologists to take the lead on a...In the Loop: Q&A with Endocrine Society Podcaster Chase Hendrickson, MD, MPH
When the Endocrine Society debuted the Endocrine Feedback Loop podcast back in 2020, it quickly took on a life of its own as host and creator Chase Hendrickson, MD, MPH, explains to Endocrine News. More than simply a new and improved journal club, the podcast seeks to educate, inform, and enlighten both listeners and the...
Fresh off of a successful ENDO 2024 in Boston in June, the Endocrine Society announced it is merging with the Association of Program Directors in Endocrinology, Diabetes, and Metabolism (APDEM). The APDEM represents the academic leaders of more than 135 training programs that prepare fellows for clinical and research careers in endocrinology and metabolism. “The Endocrine...
Two Medication Classes Reduced Cardiovascular and Liver Events in People with Type 2 Diabetes
GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data presented at ENDO 2024. Researchers reviewed Medicare data documented from 2013 to 2020 and a large U.S. health insurance database from 2013 to 2022. They performed...
Neurocrine Biosciences, Inc. on July 1 announced the U.S. Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) with Priority Review designations for crinecerfont in the treatment of children, adolescents, and adults with classic congenital adrenal hyperplasia (CAH). If approved, crinecerfont would be the first new treatment option for CAH in...
Low Socioeconomic Status Raises Pregnant Women’s Risk of Exposure to Thyroid-Disrupting Chemicals
Exposure to some endocrine-disrupting chemicals (EDCs) that harm the thyroid gland has increased over the past 20 years among U.S. women of childbearing age and pregnant women, especially among those with lower social and economic status, according to a study presented at ENDO 2024. The researchers focused this study on women who may be particularly...
